- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22:24 | Vivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update | 1 | GlobeNewswire (USA) | ||
| 17.04. | Vivos Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.04. | Vivos Therapeutics to acquire operating assets of The Sleep Center of Nevada | 1 | Seeking Alpha | ||
| 16.04. | Vivos Therapeutics, Inc: Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada | 71 | GlobeNewswire (Europe) | By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to... ► Artikel lesen | |
| 31.03. | Vivos Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | Vivos Therapeutics GAAP EPS of -$2.22 misses by $0.20, revenue of $15.03M misses by $0.17M | 5 | Seeking Alpha | ||
| 31.03. | Vivos Therapeutics, Inc: Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update | 59 | GlobeNewswire (Europe) | Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo.... ► Artikel lesen | |
| 31.03. | Vivos Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 28.03. | Earnings Outlook For Vivos Therapeutics | 2 | Benzinga.com | ||
| 18.02. | Vivos Therapeutics, Inc: Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET. | 1 | GlobeNewswire (USA) | ||
| 14.02. | Vivos Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.02. | Vivos Therapeutics announces up to $50M mixed shelf offering | 1 | Seeking Alpha | ||
| 29.01. | Vivos Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 22.01. | Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders | 1 | Seeking Alpha | ||
| 22.01. | Vivos Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 23.12.24 | Vivos Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.12.24 | Vivos Therapeutics announces $3.5 million stock offering | 2 | Investing.com | ||
| 23.12.24 | Vivos Therapeutics kündigt Aktienemission im Wert von 3,5 Millionen US-Dollar an | 3 | Investing.com Deutsch | ||
| 23.12.24 | Vivos Therapeutics, Inc: Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 10.12.24 | Cellev8 Nutrition Inc: Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress | 442 | ACCESS Newswire | WELLINGTON, FL and HIGHLANDS RANCH, CO / ACCESSWIRE / December 10, 2024 / Cellev8 Nutrition Inc. (OTC Pink:CELV) and Vivos Therapeutics, Inc. today announced a strategic joint marketing venture aimed... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 63,25 | +1,28 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Quartalsergebnis
Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose
13.05.2025 / 07:45... ► Artikel lesen | |
| INTUITIVE SURGICAL | 502,50 | -0,83 % | Intuitive Surgical Promotes President Dave Rosa As CEO | SUNNYVALE (dpa-AFX) - Intuitive Surgical, Inc. (ISRG), a biotechnology company, on Thursday announced the promotion of President Dave Rosa as Chief Executive Officer, effective from July 1.... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,129 | -5,15 % | Sernova Biotherapeutics Inc: Sernova talks interim data from Cell Pouch trial | ||
| SYNLAB | 12,940 | +0,47 % | Synlab Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| NUGEN MEDICAL DEVICES | 0,040 | -11,01 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
| PLUS THERAPEUTICS | 0,505 | -5,52 % | Plus Therapeutics Inc.: Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) | Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate immune responses Updated ReSPECT data... ► Artikel lesen | |
| CARDINAL HEALTH | 132,75 | -0,11 % | Cardinal Health Stock Outlook: Is Wall Street Bullish or Bearish? | ||
| INVITAE | - | - | Ex-Invitae Spinoff Relaunches as Citizen Health, Picks Up $14.5M in Seed Funding | ||
| ATOSSA THERAPEUTICS | 0,905 | +16,32 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen | Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics... ► Artikel lesen | |
| UNIDOC HEALTH | 0,186 | +0,54 % | UniDoc Health Corp.: UniDoc Provides Update on Marketing Engagement | VANCOUVER, BC / ACCESS Newswire / April 29, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), provides an update on its renewed engagement of Rumble Strip Media... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports First Quarter 2025 Financial Results and Provides Business Update | SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter... ► Artikel lesen | |
| FRESENIUS | 42,520 | +1,80 % | BERENBERG stuft Fresenius SE auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius von 45 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Nach dem starken Jahresstart der Aktie hätten... ► Artikel lesen | |
| UNITEDHEALTH | 245,05 | -11,15 % | UnitedHealth Group-Aktie leicht im Minus (338,6583 €) | Im US-amerikanischen Wertpapierhandel liegt die Aktie der UnitedHealth Group gegenwärtig im Minus. Die Aktie notiert derzeit bei 381,59 US-Dollar. Die UnitedHealth Group-Aktie verzeichnet aktuell ein... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 48,850 | +1,45 % | GOLDMAN SACHS stuft Siemens Healthineers auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Siemens Healthineers von 60 auf 56 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Richard Felton passte... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 50,84 | +1,68 % | Fresenius Medical Care: Analysten pessimistisch - Die Kasse klingelt! |
Das Unternehmen VIVOS THERAPEUTICS INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 3,070 Euro und damit -0,32 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVOS THERAPEUTICS INC finden Sie auf Wallstreet Online.